Synageva BioPharma names new board member
Dr Goldberg first joined Genzyme in 1996 as medical director for oncology and following several promotions, has held his current position of senior vice president of clinical research
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
The Restylane package insert will be amended to include the study results. The company anticipates using this information in its promotional activities. This randomized, evaluator-blinded, multi-center study enrolled